Search
L-arginine
go.drugbank.com/drugs/DB17289ApprovedInvestigationalNutraceuticalSalts: L-arginine hydrochlorideMixtures: Clinimix 2.5% Travasol Aa Without Electrolytes In 10% Dextrose Injec, Quick Mix 2.5% Travasol Aa With Electrolytes With 25% Dextrose InjecSulfamethoxazole
go.drugbank.com/drugs/DB01015ApprovedInvestigationalSulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. … [L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps
Mixtures: Bactrim Roche Inj, SEPTRIN IV 5 ML 10 AMPULSynonyms: 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamideSodium phosphate, dibasic
go.drugbank.com/drugs/DB14502ApprovedInvestigationalMixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)Glutamic acid
go.drugbank.com/drugs/DB00142ApprovedInvestigationalNutraceuticalA peptide that is a homopolymer of glutamic acid.
Mixtures: Aminosyn II in Dextrose, Aminosyn II in DextroseSynonyms: L-Glutamate, L-Glutamic acidLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050 … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].
Categories: Drugs Used in Diabetes, DPP-IV InhibitorsProducts: Linagliptin 1A Pharma 5 mg - FilmtablettenDasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigational[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. … [A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamideNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. … [L46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European
Copanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigationalPI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. … Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDETislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses. … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors